12:00 AM
 | 
Nov 01, 1999
 |  BC Week In Review  |  Clinical News  |  Regulatory

Aptosyn exisulind apoptosis augmenting compound regulatory update

The FDA accepted for filing CLPA's NDA for Aptosyn to treat familial...

Read the full 36 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >